Concurrent use of aromatase inhibitors and hypofractionated radiation therapy

Table 2 Treatment characteristics

Treatments	n (%)
Surgery
Surgery
Yes (BCS)	35 (53.0)1
No	31 (47.0)
Axillary LND
Yes	17 (25.8)
No	49 (74.2)
Sentinel LN
Yes	20 (30.3)
No	46 (69.7)
Aromatase inhibitor
Letrozole	16 (24.2)
Anastrozole	47 (71.2)
Exemestane	3 (4.6)
RT
Position
Lateral decubitus	63 (95.4)
Dorsal decubitus	3 (4.6)
Source
Cobalt 60	57 (86.3)
RX 4 MV	8 (12.2)
RX 6 MV	1 (1.5)
Volume
Whole breast	66 (100)
Axillary LN	4 (6.1)
Susclavicular LN	3 (4.5)
Boost	35 (4.5)
Protocol for the whole breast
5 fractions of 6.5 Gy	63 (95)
Other fractionation	3 (5)
Protocol for the boost
2 fractions of 6.5 Gy	28 (42.4)
1 fraction of 6.5 Gy	5 (7.5)
Other fractionation	2 (3)
Median duration in days (range)	29 (25-52)

¹Including five patients with neoadjuvant endocrine therapy. BCS: Breast conservative surgery; LN: Lymph node; LND: Lymph node dissection; RT: Radiation therapy.